Update on antithrombin I (fibrin)

References
1 Fenton II JW, Olson TA, Zabinski MP. et al. Anion-binding exosite of human a-thrombin and fibrin(ogen) recognition. Biochemistry 1988; 27: 7106-7112.
2 Stubbs MT, Bode W. A player of many parts: The spotlight falls on thrombin’s structure. Thromb Res 1993; 69: 1-58.
3 Howell WH. The preparation and properties of thrombin, together with observations on antithrombin and prothrombin. Am J Physiol 1910; 26: 453-473.
4 Seegers WH, Nieft M, Loomis EC. Note on the adsorption of thrombin on fibrin. Science 1945; 101: 520-521.
5 Seegers WH. Multiple protein interactions as exhibited by the blood-clotting mechanism. J Phys Colloid Chem 1947; 51: 198-206.
6 Seegers WH, Johnson JF, Fell C. An antithrombin reaction related to prothrombin activation. Am J Physiol 1954; 176: 97-103.
7 de Bosch NB, Mosesson MW, Ruiz-Sáez A. et al. Inhibition of thrombin generation in plasma by fibrin formation (AntithrombinI). Thromb Haemost 2002; 88: 253-258.
8 Mosesson MW. Antithrombin I. Inhibition of thrombin generation in plasma by fibrin formation. Thromb Haemost 2003; 89: 9-12.
9 Liu CY, Nossel HL, Kaplan KL. Defective thrombin binding by abnormal fibrin associated with recurrent thrombosis. Thromb Haemost 1979; 42: 79 (abstract).
10 Meh DA, Siebenlist KR, Mosesson MW. Identification and characterization of the thrombin binding sites on fibrin. J Biol Chem 1996; 271: 23121-23125.
11 Mosesson MW, Finlayson JS, Umfleet RA. Human fibrinogen heterogeneities. III. Identification of g chain variants. J Biol Chem 1972; 247: 5223-5227.
12 Wolfenstein-Todel C, Mosesson MW. Carboxy-terminal amino acid sequence of ahuman fibrinogen γ chain variant (γ’). Biochemistry 1981; 20: 6146-6149.
13 Pechik I, Madrazo J, Mosesson MW. et al. Crystal structure of the complex between thrombin and the central “E“region of fibrin. Proc Natl Acad Sci USA 2004; 101: 2718-2723.
14 Pospisil CH, Stafford AR, Fredenburgh JC. et al. Evidence that both exosites on thrombin participate in its high affinity interaction with fibrin. J Biol Chem 2003; 278: 21584-21591.
15 Lovely RS, Moaddel M, Farrell DH. Fibrinogen γ’ chain binds thrombin exosite II. J Thromb Haemost 2003; 1: 124-131.
16 Pineda AO, Chen ZW, Marino F. et al. Crystal structure of thrombin in complex with fibrinogen gamma’ peptide. Biophys Cem 2007; 25: 556-559.
17 Meh DA, Siebenlist KR, Brennan SO. et al. The amino acid sequences in fibrin responsible for high affinity thrombin binding. Thromb Haemost 2001; 85: 470-474.
18 Meh DA, Mosesson MW, Siebenlist KR. et al. Fibrinogen Naples I (Bb A68T) non-substrate thrombin binding capacities. Thromb Res 2001; 103: 63-73.
19 Siebenlist KR, Mosesson MW, Hernandez I. et al. Studies on the basis for the properties of fibrin produced from fibrinogen containing g’ chains. Blood 2005; 106: 2730-2736.
20 Di Cera E, Dang QD, Ayala YM. Molecular mechanisms of thrombin function. Cell Mol Life Sci 1997; 53: 701-730.
21 Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264: 4743-4746.
22 Cooper AV, Standeven KF, Ariens RA. Fibrinogen gamma-chain splice variant gamma‘alters fibrin formation and structure. Blood 2003; 102: 535-540.
23 Fredenburgh JC, Stafford AR, Weitz JI. Evidence for allosteric linkage between exosites 1 and 2 of thrombin. J Biol Chem 1997; 272: 25493-25499.
24 Bock LC, Griffin LC, Latham JA. et al. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 1992; 355: 564-566.
25 Liaw PC, Fredenburgh JC, Stafford AR. et al. Localization of the thrombin-binding domain on prothrombin fragment 2. J Biol Chem 1998; 273: 8932-8939.
26 Li CQ, Vindigni A, Sadler JE. et al. Platelet glycoprotein Ib alpha binds to thrombin anion-binding exosite II inducing allosteric changes in the activity of thrombin. J Biol Chem 2001; 276: 6161-6168.
27 Colwell NS, Blinder MA, Tsiang M. et al. Allosteric effects of a monoclonal antibody against thrombin exosite II. Biochemistry 1998; 37: 15057-15065.
28 Tasset DM, Kubik MF, Steiner W. Oligonucleotide inhibitors of human thrombin that bind distinct epitopes. J Mol Biol 1997; 272: 688-698.
29 Credo RB, Curtis CG, Lorand L. Ca²⁺-related regulatory function of fibrinogen. Proc Natl Acad Sci USA 1978; 75: 4234-4237.
30 Janus TJ, Lewis SD, Lorand L. et al. Promotion of thrombin-catalyzed activation of factor XIII by fibrinogen. Biochemistry 1983; 22: 6268-6272.
31 Greenberg CS, Miraglia CC, Rickles FR. et al. Cleavage of blood coagulation factor XIII and fibrinogen by thrombin during in vitro clotting. J Clin Invest 1985; 75: 1463-1470.
32 Naski MC, Lorand L, Shafer JA. Characterization of the kinetic pathway for fibrin promotion of alphathrombin-catalyzed activation of plasmafactor XIII. Biochemistry 1991; 30: 934-941.
33 Francis CW, Kraus DH, Marder VJ. Structural and chromatographic heterogeneity of normal plasma fibrinogen associated with the presence of three gamma-chain types with distinct molecular weights. Biochim Biophys Acta 1983; 744: 155-164.
34 Francis CW, Keele EM, Marder VJ. Purification of three gamma-chains with different molecular weights from normal human plasma fibrinogen. Biochim Biophys Acta 1984; 797: 328-335.
35 Francis CW, Muller E, Henschen A. et al. Carboxy-terminal amino acid sequences of two large variant forms of the human plasma fibrinogen? chain. Proc Natl Acad Sci USA 1988; 85: 3358-3362.
36 Mosesson MW, Hernandez I, Raife TJ. et al. Plasma fibrinogen gamma’ chain content in the thrombotic microangiopathy syndrome. J Thromb Haemost 2007; 5: 62-69.
37 Koopman J, Haverkate F, Lord ST. et al. Molecular basis of fibrinogen Naples associated with defective throm binbinding and thrombophilia. Homozygous substitution of B beta 68 Ala-->Thr. J Clin Invest 1992; 90: 238-244.
38 Di Minno G, Martinez J, Cirillo F. et al. A role for platelets and thrombin in the juvenile stroke of two siblings with defective thrombin-absorbing capacity of fibrin(ogen). Arterioscl Thromb 1991; 11: 785-796.
39 Caen J, Faur Y, Inceman S. et al. Nécrose ischémique bilatérale dans un cas de grande hypofibrinogénémie congénitale. Nouv Rev FrHématol 1964; 4: 321-326.
40 Marchal G, Duhamel G, Samama M. et al. Thrombose massive des vaisseaux d‘un membre au cours d‘une hyp of ibrinémie congénitale. Hémostase 1964; 4: 81-89.
41 Nilsson IM, Niléhn J-E, Cronberg S. et al. Hypofibrinogenemia and massive thrombosis. Acta Medica Scand 1966; 180: 65-76.
42 Ingram GI, McBrien DJ, Spencer H. Fatal pulmonary embolism in congenital fibrinopenia. Acta Haematol 1966; 35: 56-62.
43 Mackinnon HH, Fekete JF. Congenital afibrinogenemia: vascular changes and multiple thrombosis induced by fibrinogen infusionsand contraceptive medication. Can Med Assoc J 1971; 140: 597-599.
44 Cronin C, Fitzpatrick D, Temperly I. Multiple pulmonary emboli in apatient with afibrinogenaemia. Acta Haematol 1988; 7: 53-54.
45 Drai E, Taillan B, Schneider S. et al. Thrombose portale révélatrice d‘une afibrinogénémie congénitale. La Presse Médicale 1992; 21: 1820-1821.
46 Chafa O, Chellali T, Sternberg C. et al. Severe hypofibrinogenemia associated with bilateral ischemic necrosis of toes and fingers. Blood Coag Fibrinolysis 1995; 6: 549-552.
47 Dupuy E, Soria C, Molho P. et al. Embolized ischemic lesions of toes in an afibrinogenemic patient: possible relevance to in vivo circulating thrombin. Thromb Res 2001; 102: 211-219.
48 de Bosch N, Sáez A, Soria C. et al. Coagulation profile in afibrinogenemia. Thromb Haemost. 1997 (Suppl): 625 (abstract).
49 Korte W, Feldges A. Increased prothrombin activation in a patient with congenital afibrinogenemia is reversible by fibrinogen substitution. Clin Invest 1994; 72: 396-398.
50 Ni H, Denis CV, Subbarao S. et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest 2000; 106: 385-392.
51 Drouet L, Paolucci F, Pasqualini N. et al. Plasma gamma’/gamma fibrinogen ratio, amarker of arterial thrombotic activity: a new potential cardiovascular risk factor?. Blood Coagul Fibrinolysis 1999; 10 (Suppl. 01) S35-S39.
52 Lovely RS, Falls LA, Al Mondhiry HA. et al. Association of γA/γ‘fibrinogen levels and coronary artery disease. Thromb Haemost 2002; 88: 26-31.
53 Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ. et al. Genetic variation in the fibrinogen gamma gene increases therisk of deep venous thrombosis by reducing plasma fibrinogen γ‘levels. Blood 2005; 106: 4176-4183.
54 vander Meer FJ, Koster T, Vandenbroucke JP. et al. The Leiden Thrombophilia Study (LETS). Thromb Haemost 1997; 78: 631-635.
55 Manilla MN, Lovely RS, Kazmierczak SC. et al. Elevated plasma fibrinogen g’ concentration is associated with myocardial infarction: effects of variationin fibrinogen genes and environmental factors. J Thromb Haemost 2007; 5: 766-733.
56 Carter WJ, Cama E, Huntington JA. Crystal structure of thrombin bound to heparin. J Biol Chem 2005; 280: 2745-2749.
57 Becker DL, Fredenburgh JC, Stafford AR. et al. Exosites 1 and 2 are essential for protection of fibrinbound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II. J Biol Chem 1999; 274: 6226-6233.